Thind G S
Compr Ther. 1980 Mar;6(3):36-42.
There are very few areas of clinical pharmacology being pursued as vigorously as hypertension. Numerous new drugs are being discovered and tested both in United States and overseas. The most promising new antihypertensive drugs seem to fall into the angiotensin-renin blocker group and those affecting the sodium-volume axis in hypertensive patients. We can look forward to newer agents that are efficacious as monotherapy and on a daily or twice daily dosage regimen for the treatment of the vast majority of hypertensive patients. There is further hope that preoperative evaluation with angiotensin blockers in patients with renovascular hypertension may improve the predictability of successful renal bypass surgery.
临床药理学中，没有几个领域像高血压研究这样积极活跃。在美国和海外，大量新药正在被研发和测试。最有前景的新型抗高血压药物似乎属于血管紧张素 - 肾素阻滞剂类别，以及那些影响高血压患者钠 - 容量轴的药物。我们有望看到新型药物，它们作为单一疗法有效，并且采用每日一次或每日两次的给药方案，可用于治疗绝大多数高血压患者。进一步的希望是，对肾血管性高血压患者使用血管紧张素阻滞剂进行术前评估，可能会提高肾搭桥手术成功的可预测性。
